Continuity Biosciences Appoints Josephine Torrente and Joseph DeSimone, PhD to Board of Directors
Josephine M. Torrente Current Role: Director, Hyman, Phelps & McNamara, P.C., the largest dedicated FDA regulatory law firm in the U.S.
Director, Hyman, Phelps & McNamara, P.C., the largest dedicated FDA regulatory law firm in the U.S. Experience: Over 30 years advising pharmaceutical and biotechnology companies on FDA regulatory strategy, product development, and lifecycle management
Over 30 years advising pharmaceutical and biotechnology companies on FDA regulatory strategy, product development, and lifecycle management Strategic Contribution: Ms. Torrente's deep regulatory insight will guide Continuity's clinical development and FDA engagement strategies as the company scales its pipeline
Dr. Joseph M. DeSimone Current Role: Sanjiv Sam Gambhir Professor of Translational Medicine and Chemical Engineering, Stanford University
Sanjiv Sam Gambhir Professor of Translational Medicine and Chemical Engineering, Honors and Recognition: National Medal of Technology and Innovation recipient; inventor on 200+ patents; author of 350+ scientific publications; One of only 25 people elected into all three US National Academies- Science, Engineering and Medicine
National Medal of Technology and Innovation recipient; inventor on 200+ patents; author of 350+ scientific publications; One of only 25 people elected into all three US National Academies- Science, Engineering and Medicine Entrepreneurial Leadership: Co-founder of Carbon (developer of CLIP 3D printing); founder of Focal Medical (acquired by Continuity) and PinPrint , a 3D microdispensing platform in which Continuity has made a strategic investment
Co-founder of (developer of CLIP 3D printing); founder of (acquired by Continuity) and , a 3D microdispensing platform in which Continuity has made a strategic investment Strategic Contribution: Dr. DeSimone's expertise in materials science, digital manufacturing, and drug delivery perfectly aligns with Continuity's platform focus on localized, precision therapeutics
Executive Commentary
"We are honored to welcome Josephine and Joe to our Board," said Bob Whitehead , Co-Founder and Executive Chairman of Continuity Biosciences. "Josephine's regulatory acumen and clear-eyed judgment are second to none. Joe is not only a visionary in drug delivery but also a trusted partner in our efforts through Focal Medical and PinPrint. Their expertise will be instrumental as we continue to scale our programs and build long-term value."
Torrente and DeSimone join Continuity's existing Board of Directors, which includes Bob Whitehead and Ramakrishna Venugopalan , PhD, MBA (Continuity's co-founders), Monica Reed , MD, Mike Fowler , and Allen Weiss . Krishna Venugopalan formerly led combination product development at AbbVie, contributing to flagship therapies Skyrizi and the newly launched Vyalev —both high-impact combination products
formerly led combination product development at AbbVie, contributing to flagship therapies and the newly launched —both high-impact combination products Mike Fowler is CEO of Affordable Housing Partners, Inc., which is a subsidiary of Berkshire Hathaway
is CEO of Affordable Housing Partners, Inc., which is a subsidiary of Berkshire Hathaway Allen Weiss served as the President of Worldwide Operations for Walt Disney Parks and Resorts (now known as Disney Parks, Experiences and Products)
served as the President of Worldwide Operations for and Resorts (now known as Disney Parks, Experiences and Products) Monica Reed is CEO of UChicago Medicine AdventHealth, where she oversees the strategic development and growth of the health system's Great Lakes Region, including four hospitals and more than 50 sites of care
About Continuity Biosciences
Founded in 2024, Continuity Biosciences is developing advanced delivery platforms for biologics and complex therapeutics, with a focus on precision targeting and tunable release. Operating in Houston (TX), Raleigh (NC), Bradenton (FL), and Torino ( Italy ), Continuity's pipeline spans oncology, metabolic diseases, infectious diseases, and women's health. Through strategic acquisitions—including Focal Medical—and targeted investments like PinPrint, Continuity is building a differentiated platform to transform the delivery of challenging therapeutics.
SOURCE Continuity Biosciences LLC
Maddie Brown, Director of Operations, Continuity Biosciences, [email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
an hour ago
- Cision Canada
Triojection® from SpinaFX Granted Breakthrough Device Designation by U.S. FDA for Minimally Invasive Lumbar Disc Treatment
TORONTO, Aug. 15, 2025 /CNW/ - SpinaFX Medical Inc., ("SpinaFX") a leading innovator in image-guided interventional spine care, is proud to announce that its flagship device, Triojection®, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA). This milestone acknowledges Triojection's potential to offer a highly effective, more accessible, and safer treatment for patients suffering from contained lumbar disc herniations, a condition recognized as one of the most common causes of disability worldwide. The Breakthrough Devices Program is designed to expedite the development and review of medical devices that demonstrate clear advantages over existing technologies for serious or life-threatening conditions. This designation grants SpinaFX prioritized access to the FDA, fostering a collaborative approach to regulatory processes and accelerating the path toward commercialization and clinical availability. A Technological Leap in Spine Care Triojection is a minimally invasive, image-guided procedure that leverages a proprietary oxygen-ozone delivery system to reduce pressure within the disc and alleviate nerve compression. Unlike more invasive surgical approaches or prolonged conservative treatments that may fail to provide relief, Triojection offers a targeted, outpatient solution that can be performed in a variety of healthcare settings from hospitals and ambulatory surgical centers to clinics in emerging markets. The device meets the FDA's stringent Breakthrough criteria: Providing a unique, novel and more effective treatment for patients with contained disc herniations. Representing a true technological innovation in the spinal care landscape. Demonstrating significant advantages in terms of safety, recovery time, cost, and accessibility. Showing strong potential to improve outcomes across diverse economic and geographic contexts, including under-resourced health systems. Meeting an Urgent Global Need Lumbar disc herniation affects millions of people globally and is a leading contributor to chronic pain, loss of mobility, reduced productivity, and diminished quality of life. Existing treatments often fall into two extremes: conservative care, which may not always bring relief, or invasive surgery, which carries risks, high costs, and extended recovery times. Triojection fills a critical therapeutic gap. It offers an evidence-based, low-barrier, cost-effective alternative that can be deployed rapidly and with minimal infrastructure ideal for both advanced and developing market health systems. "Our mission is to transform spine care and make meaningful minimalist solutions accessible to all," said Prof. Kieran Murphy MD, Chairman, Founder and Chief Medical Officer at SpinaFX. "This designation by the FDA validates the scientific merit of Triojection and 21 years of work by many people who have helped get us to this point. It's a vote of confidence in the future of inventiveness in spine health. We sincerely thank all our investors for their support and trust." Backed by Global Expertise and Scientific Rigor This regulatory milestone is the result of over two decades of research and development, including multiple international studies and collaborations with leading clinical experts in Italy, Switzerland, Greece, the United States and Canada. SpinaFX acknowledges the contributions of its diverse network of engineers and investigators, including Prof. Mario Muto (Italy) and Prof. Alexis Kelekis (Greece), both pioneers in the field of Interventional Neuroradiology. Clinical data supporting Triojection's efficacy continues to build, with upcoming publications expected to highlight its outcomes across multicenter trials. The company's engineering, regulatory, and clinical affairs teams along with trusted partners across Europe and the United States have played a critical role in advancing the technology toward approval and adoption. A Platform for Future Innovation Beyond this first indication, SpinaFX is exploring additional applications of its oxygen-ozone delivery platform in treating other disc-related conditions and musculoskeletal disorders. The company is also expanding its educational programs to train physicians in safe, effective, and evidence-based use of the Triojection procedure. "Our team is honored to receive this designation, but we view it as just the beginning," said Jeff Cambra, CEO of SpinaFX. "We're committed to working hand-in-hand with the FDA to bring Triojection to patients in the U.S. and beyond. Our goal is to create a new standard in spine care that's efficient, scalable, and deeply patient-centered. " About SpinaFX SpinaFX Medical Inc. is a Canadian-based medical technology company specializing in minimally invasive, image-guided therapies for spinal disorders. Its proprietary technology platform offers non-surgical solutions for treating disc-related conditions, using a unique approach to oxygen-ozone therapy. Committed to democratizing access to advanced spine care, SpinaFX collaborates with leading academic institutions, clinicians, and healthcare providers across the globe. Forward-Looking Statement This news release contains predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance, referred to herein as "forward-looking statements", which are made as of the date of this news release or as of the effective date of information described in this release, as applicable. The forward-looking statements address anticipated events or occurrences which may include economic factors, industry trends, market demand, and corporate performance and profitability, that may have an impact on SpinaFX's success. Forward-looking statements are often identified through words or expressions including "expects", "anticipates", "plans", "projects", "estimates", "envisages", "assumes", "intends", "strategy", "goals", "objectives" or variations thereof or stating that certain actions, events or results "may", "can", "could", "would", "might" or "will" be taken, occur or be achieved, or the negative of any of these terms and similar expressions. All forward-looking statements are based on current beliefs as well as various assumptions made by, and information currently available to SpinaFX's management team. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that estimates, forecasts, projections, and other forward-looking statements will not be achieved or that assumptions do not reflect future experience. We caution any person reviewing this news release not to place undue reliance on these forward-looking statements as several important factors could cause the actual outcomes to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates, assumptions and intentions expressed in such forward-looking statements. Neither SpinaFX nor its representatives undertake to update any forward-looking statement, whether written or oral, that may be made from time to time by SpinaFX or its representatives or on behalf of either of them, except as may be required by law.
Calgary Herald
17 hours ago
- Calgary Herald
Man asks ChatGPT for advice on how to cut salt, ends up in hospital with hallucinations
Article content 'However, when we asked ChatGPT 3.5 what chloride can be replaced with, we also produced a response that included bromide. Though the reply stated that context matters, it did not provide a specific health warning, nor did it inquire about why we wanted to know, as we presume a medical professional would do.' Article content The man already followed a very restrictive diet, one that doctors found was impacting his levels of important micronutrients, like vitamin C and B12. He was also reportedly very thirsty, but at the same time very worried about the quality of the water he was being offered, since he distilled his own water. He was thoroughly tested and first kept at the hospital for electrolyte monitoring and repletion. Article content His test results, combined with the hallucinations, and other reported symptoms, including new facial acne, fatigue and insomnia, led the medical staff to believe the patient had bromism. Article content Article content Bromism, a condition that was mostly reported in the early 20th century, is caused by ingesting high quantities of sodium bromide. The normal levels of bromide are between 0.9 to 7.3 mg/L, but this patient had 1,700 mg/L. Article content The patient remained in the hospital for treatment for three weeks, and was stable at his check-up two weeks after his discharge. Article content Bromism cases decreased after the U.S. Food and Drug Administration (FDA) eliminated the use of bromide in the 1980s, the authors wrote. It was previously used in treatments for insomnia, hysteria and anxiety. However, the disease has reemerged now, with bromide being added to some unregulated dietary supplements and sedatives and the consumption of excess dextromethorphan, a substance included in cough medicine. Article content 'While cases of bromism may remain relatively rare, it remains prudent to highlight bromism as a reversible cause of new-onset psychiatric, neurologic, and dermatologic symptoms, as bromide-containing substances have become more readily available with widespread use of the internet,' the authors wrote. Article content Article content The doctors said that AI tools can be great for creating a bridge between scientists and the general population, but it also carries a risk of producing misinformation and giving information out of context, something that doctors are trained not to do. Article content 'As the use of AI tools increases, providers will need to consider this when screening for where their patients are consuming health information,' the authors said in the case study. Article content OpenAI, the company that created ChatGPT, recently announced changes to their system, including being more careful when it comes to health-related questions. In one of the examples, the chatbot gives information but also includes a note about checking in with a health professional. Article content 'Our terms say that ChatGPT is not intended for use in the treatment of any health condition, and is not a substitute for professional advice. We have safety teams working on reducing risks and have trained our AI systems to encourage people to seek professional guidance,' OpenAI said in a statement.
Globe and Mail
a day ago
- Globe and Mail
Abbott Taps Growing TMVR Market With Tendyne System
Abbott Laboratories ABT recently received Food and Drug Administration ('FDA') approval for its Tendyne transcatheter mitral valve replacement (TMVR) system. The Tendyne system replaces mitral valves that are not functioning properly due to severe mitral annular calcification (MAC). The Tendyne system expands the company's comprehensive Structural Heart portfolio. The rising prevalence of mitral valve diseases, growing preferences for minimally invasive procedures and expanding geriatric population has driven the adoption of TMVR system. Investors are eyeing this fast-growing market, which is projected to witness a compound annual growth rate of 20% from 2025 to 2030 (Per a Medi-Tech Insights report). MAC stiffens the structure of the mitral valve and can lead to mitral regurgitation or stenosis that disrupts the heart's ability to pump blood effectively. The complex nature of this mitral valve disease and patients' specific needs and health conditions can pose challenges for surgical correction. The Tendyne system offers an alternative, minimally invasive way to replace the valve of patients with severe MAC who are at high risk for open-heart surgery. The innovative and unique design of the Tendyne system and the valve's availability in multiple sizes allow it to adapt to a range of patient anatomies. The self-expanding valve is delivered through a small incision in the chest and then advanced into the heart to replace the mitral valve. The valve is fully repositionable and retrievable during implantation, allowing for the best possible outcome for people requiring a valve replacement. Offerings By ABT's Peers in the Structural Heart Field Edwards Lifesciences EW makes significant investments in the development of transcatheter heart valve repair and replacement technologies designed to treat mitral and tricuspid valve diseases. The company's PASCAL Precision system addresses the needs of patients with mitral or tricuspid regurgitation through leaflet approximation. The EVOQUE system is the world's first transcatheter tricuspid valve replacement therapy to receive regulatory approval. It addresses tricuspid valve regurgitation by replacing the native valve with a bioprosthetic valve. In addition, SAPIEN M3 transcatheter mitral valve replacement system is designed specifically for patients with symptomatic mitral regurgitation. Medtronic 's MDT Structural Heart & Aortic division offers therapies for heart valve disorders and aortic disease. Key products include the CoreValve family (Evolut PRO, PRO+, FX, FX+ TAVR systems), surgical valve replacement and repair solutions (tissue and mechanical), blood-handling systems, surgical ablation technologies, and positioning/stabilization tools. The company also provides endovascular stent grafts and accessories like the Endurant II Stent Graft System (abdominal aortic aneurysms), Valiant Captivia Thoracic Stent Graft System (thoracic repair) and Heli-FX EndoAnchor System. ABT Price Performance In the past year, Abbott shares have surged 19.2%, outperforming the industry's 6.2% growth. The S&P 500 composite grew 17.8% in the same period. Image Source: Zacks Investment Research Discounted Valuation ABT currently trades at a forward 12-month Price-to-Sales (P/S) of 4.87X compared with the industry average of 5.56X. Image Source: Zacks Investment Research ABT Stock Estimate Trend In the past 30 days, Tempus AI's EPS estimate has moved south 0.2% for 2025. Image Source: Zacks Investment Research ABT stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops." Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.5% per year. So be sure to give these hand picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report This article originally published on Zacks Investment Research (
